SLC45A4-mediated putrescine uptake functionally modulates HOXA1 and promotes bortezomib resistance in multiple myeloma

Authors:

Abstract
Background: Bortezomib resistance remains a major barrier to durable responses in multiple myeloma, but how metabolic adaptation within the bone marrow niche sustains this phenotype remains incompletely understood. Methods: We integrated metabolomic profiling, isotope tracing, bulk RNA sequencing, single-cell RNA sequencing, co-culture tracing, molecular perturbation assays, protein–metabolite binding analyses, and pharmacological screening to investigate the role of SLC45A4-mediated putrescine uptake in bortezomib resistance. Results: Bortezomib-resistant myeloma cells preferentially accumulated putrescine through enhanced uptake rather than de novo polyamine biosynthesis. SLC45A4 was upregulated in resistant CD138⁺ myeloma cells and promoted putrescine import and bortezomib resistance. Mechanistically, SLC45A4-mediated putrescine accumulation was accompanied by increased HOXA1 recovery in putrescine-associated fractions and enhanced HOXA1-associated NF-κB signaling. Single-cell and co-culture tracing analyses further suggested that MDSCs in the bone marrow niche serve as a source of putrescine acquired by myeloma cells. Pharmacological suppression of this axis by abiraterone acetate, alone or combined with the HOX/PBX inhibitor HXR9, attenuated the resistance-associated phenotype. Conclusions: These findings identify an MDSC-supported SLC45A4–putrescine–HOXA1–NF-κB axis as a metabolic mechanism contributing to bortezomib resistance in multiple myeloma and nominate niche-dependent metabolic crosstalk as a potential therapeutic vulnerability.
Funding Information
  • National Natural Science Foundation of China (82303451)
  • Research Funds of Jinfeng Laboratory (JFLKYXM202503AZ-203)